Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | IDH1 | O75874 | 5/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3450501 | 0.87 | HDAC3 (0.44) | SYKCDK1CDK2IGF1RHDAC3 | |
| SCHEMBL3449867 | 0.86 | SELP (0.38) | GRM5SYKCDK1CDK2IGF1R | |
| SCHEMBL3344744 | 0.82 | SYK (0.56) | GRM5SYKCDC7CDK1CDK2 | |
| SCHEMBL3447995 | 0.80 | IGF1R (0.47) | SYKCDK2IGF1RHDAC3HDAC1 | |
| SCHEMBL3449648 | 0.79 | GRM5 (0.51) | GRM5SYKIDH1CDC7CDK1 | |
| SCHEMBL3348225 | 0.75 | IGF1R (0.55) | SYKCDK2IGF1RHDAC3HDAC1 | |
| SCHEMBL3449221 | 0.74 | KDR (0.42) | SYKCDK1CDK2IGF1RKDR | |
| SCHEMBL13310694 | 0.72 | IDH1 (0.47) | GRM5SYKIDH1CDC7IDH2 | |
| SCHEMBL3350947 | 0.71 | MAPK1 (0.51) | SYKIGF1R | |
| SCHEMBL4584347 | 0.69 | IGF1R (0.48) | SYKCDK1CDK2IGF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | GRM5 4055/4885SYK 804/4885IDH1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.